Weiss Lukas, Huemer Florian, Mlineritsch Brigitte, Greil Richard
3rd Medical Department of Hematology, Medical Oncology, Hemostaseology, Rheumatology and Infectious Disease, Salzburg Cancer Research Institute (SCRI), Muellner Hauptstraße 48, 5020 Salzburg, Austria.
Memo. 2016;9:82-84. doi: 10.1007/s12254-016-0267-3. Epub 2016 Jun 2.
Increased numbers of tumour infiltrating T‑cells have long been associated with a better prognosis in ovarian cancer, which has led to the general assumption of a relevant impact of T‑cellular anti-tumour immunity in this disease. As a consequence of this knowledge, a multitude of immunologic therapies has emerged over the past years. Although some reports could evidence a successful induction of anti-tumour T‑cells, in general, these attempts did not translate into clinically significant activity. As has already been shown in other tumour entities, immune checkpoint blockade - mainly antibodies directed against PD-1 and PD-L1 - could possibly become a real "game changer" in ovarian cancer in the future.
长期以来，肿瘤浸润性T细胞数量增加与卵巢癌较好的预后相关，这使得人们普遍认为T细胞抗肿瘤免疫在这种疾病中具有重要影响。基于这一认识，在过去几年中出现了大量免疫疗法。尽管一些报告能够证明成功诱导了抗肿瘤T细胞，但总体而言，这些尝试并未转化为具有临床意义的活性。正如在其他肿瘤实体中已经显示的那样，免疫检查点阻断——主要是针对PD-1和PD-L1的抗体——未来可能会成为卵巢癌真正的“改变游戏规则者”。
